• 850-433-1141 | info@wpnnradio.com | Text line: 850-790-5300

Business

Student loan borrowers await Biden plan on debt forgiveness

Student loan borrowers await Biden plan on debt forgiveness 150 150 admin

WASHINGTON (AP) — Millions of Americans were waiting to learn the fate of their federal student debt on Wednesday as President Joe Biden prepared to deliver on his campaign promise to provide up to $10,000 in debt cancellation.

Details of the plan have been kept closely guarded, but borrowers who earn less than $125,000 a year would be eligible for the loan forgiveness, according to three people familiar with the decision. Biden is also set to extend a pause on federal student loan payments through January.

If it survives legal challenges that are almost certain to come, Biden’s plan could offer a windfall to a swath of the nation in the run-up to this fall’s midterm elections. More than 43 million owe a combined $1.6 trillion in federal student debt, with almost a third owing less than $10,000, according to federal data.

Still, the action is unlikely to thrill any of the factions that have been jostling for influence as Biden weighs how much to cancel and for whom.

Biden has faced pressure from liberals to provide broader relief to hard-hit borrowers, and from moderates and Republicans questioning the fairness of any widespread forgiveness. The delay in Biden’s decision has only heightened the anticipation for what his own aides acknowledge represents a political no-win situation. The people spoke on the condition of anonymity to discuss Biden’s intended announcement ahead of time.

The continuation of the pandemic-era payment freeze comes just days before millions of Americans were set to find out when their next student loan bills will be due. This is the closest the administration has come to hitting the end of the payment freeze extension, with the current pause set to end Aug. 31.

Wednesday’s announcement was set for the White House after Biden returns from vacation in Rehoboth Beach, Delaware. The administration had briefly considered higher education schools in the president’s home state for a larger reveal, but scaled back their plans.

During the 2020 presidential campaign, Biden was initially skeptical of student loan debt cancellation as he faced off against more progressive candidates for the Democratic nomination. Sens. Elizabeth Warren, D-Mass., and Bernie Sanders, I-Vt., had proposed cancellations of $50,000 or more.

As he tried to shore up support among younger voters and prepare for a general election battle against President Donald Trump, Biden unveiled his initial proposal for debt cancellation of $10,000 per borrower, with no mention of an income cap.

Biden narrowed his campaign promise in recent months by embracing the income limit as soaring inflation took a political toll and as he aimed to head off political attacks that the cancellation would benefit those with higher take-home pay. But Democrats, from members of congressional leadership to those facing tough reelection bids this November, have pushed the administration to go as broad as possible on debt relief, seeing it in part as a galvanizing issue, particularly for Black and young voters this fall.

The frenzied last-minute lobbying continued Tuesday even as Biden remained on his summer vacation. Senate Majority Leader Chuck Schumer, D-N.Y., one of the loudest advocates in recent years for canceling student loan debt, spoke privately on the phone with Biden, imploring the president to forgive as much debt as the administration can, according to a Democrat with knowledge of the call.

In his pitch, Schumer argued to Biden that doing so was the right thing morally and economically, said the Democrat, who asked for anonymity to describe a private conversation.

Inside the administration, officials have discussed since at least early summer forgiving more than $10,000 of student debt for certain categories of borrowers, such as Pell Grant recipients, according to three people with knowledge of the deliberations. That remained one of the final variables being considered by Biden heading into Wednesday’s announcement.

Democrats are betting that Biden, who has seen his public approval rating tumble over the last year, can help motivate younger voters to the polls in November with the announcement.

Although Biden’s plan is narrower than what he initially proposed during the campaign, “he’ll get a lot of credit for following through on something that he was committed to,” said Celinda Lake, a Democratic pollster who worked with Biden during the 2020 election.

She described student debt as a “gateway issue” for younger voters, meaning it affects their views and decisions on housing affordability and career choices. A survey of 18- to 29-year-olds conducted by the Harvard Institute of Politics in March found that 59% of those polled favored debt cancellation of some sort — whether for all borrowers or those most in need — although student loans did not rank high among issues that most concerned people in that age group.

Some advocates were already bracing for disappointment.

“If the rumors are true, we’ve got a problem,” Derrick Johnson, the president of the NAACP, which has aggressively lobbied Biden to take bolder action, said Tuesday. He emphasized that Black students face higher debut burdens than white students.

“President Biden’s decision on student debt cannot become the latest example of a policy that has left Black people — especially Black women — behind,” he said. “This is not how you treat Black voters who turned out in record numbers and provided 90% of their vote to once again save democracy in 2020.”

John Della Volpe, who worked as a consultant on Biden’s campaign and is the director of polling at the Harvard Kennedy School Institute of Politics, said the particulars of Biden’s announcement were less important than the decision itself.

“It’s about trust in politics, in government, in our system. It’s also about trust in the individual, which in this case is President Biden,” Della Volpe said.

Combined with fears about expanding abortion restrictions and Trump’s reemergence on the political scene, Della Volpe said student debt forgiveness “adds an additional tailwind to an already improving position with young people.”

Republicans, meanwhile, see only political upside if Biden pursues a large-scale cancellation of student debt ahead of the November midterms, anticipating backlash for Democrats — particularly in states where there are large numbers of working-class voters without college degrees. Critics of broad student debt forgiveness also believe it will open the White House to lawsuits, on the grounds that Congress has never given the president the explicit authority to cancel debt on his own.

The Republican National Committee on Tuesday blasted Biden’s expected announcement as a “handout to the rich,” claiming it would unfairly burden lower-income taxpayers and those who have already paid off their student loans with covering the costs of higher education for the wealthy.

“My neighbor, a detective, worked 3 jobs (including selling carpet) & his wife worked to make sure their daughter got quality college degree w/no student debt,” Rep. Kevin Brady, R-Texas, the top Republican on the House Ways and Means Committee, tweeted Tuesday. “Big sacrifice. Now their taxes must pay off someone else’s student debt?”

Biden’s elongated deliberations have sent federal loan servicers, who have been instructed to hold back billing statements while Biden weighed a decision, grumbling.

Industry groups had complained that the delayed decision left them with just days to notify borrowers, retrain customer service workers and update websites and digital payment systems, said Scott Buchanan, executive director of the Student Loan Servicing Alliance.

It increases the risk that some borrowers will inadvertently be told they need to make payments, he said.

“At this late stage I think that’s the risk we’re running,” he said. “You can’t just turn on a dime with 35 million borrowers who all have different loan types and statuses.”

___

AP Education Writer Collin Binkley in Washington contributed to this report.

source

Factbox-Asia’s richest man Adani on deals spree in India, abroad

Factbox-Asia’s richest man Adani on deals spree in India, abroad 150 150 admin

NEW DELHI (Reuters) – Indian billionaire Gautam Adani, Asia’s richest man, is making his biggest media bet with a bid to buy a majority stake in New Delhi Television (NDTV).

Adani’s coal-to-edible-oils conglomerate has been on a deals spree over the past two years.

BUYS:

MEDIA

A unit of the Adani group used financial rights in a bid to buy a 29.18% stake in NDTV, apart from an open offer for another 26% in line with Indian regulations. Adani announced the move on Aug. 23 but NDTV, which has a market valuation of about $300 million, said its consent was not sought.

POWER

Adani Power Ltd, India’s largest private thermal power producer, said on Aug. 19 that it would buy thermal power plant operator DB Power for an enterprise value of 70.17 billion rupees ($878.61 million).

ROAD ASSETS

Adani Enterprises said on Aug. 4 that a unit would buy Macquarie Asia Infrastructure Fund’s India toll roads in Andhra Pradesh and Gujarat states for 31.10 billion rupees.

PORT

Israel said on July 14 that it would sell Haifa Port, a major trade hub on its Mediterranean coast, to Adani Ports and local chemicals and logistics group Gadot for 4.1 billion shekels ($1.18 billion).

CEMENT

The Adani Group said in mid-May that it would buy Holcim AG’s cement businesses in India for $10.5 billion, its largest-ever acquisition, to become the country’s No. 2 cement manufacturer.

SALES:

RENEWABLES

* French energy major TotalEnergies said in June that it would buy a 25% stake in Adani New Industries Ltd, as part of a deal with Adani Enterprises to develop the world’s biggest green hydrogen ecosystem.

* Total said in January 2021 that it was paying $2.5 billion for a share in Adani Green Energy Ltd and its solar power assets.

($1 = 79.8650 Indian rupees)

(Compiled by Krishna N. Das; Editing by Muralikumar Anantharaman)

source

Twitter misled U.S. regulators on hackers, spam, whistleblower says

Twitter misled U.S. regulators on hackers, spam, whistleblower says 150 150 admin

By Chavi Mehta

(Reuters) – Twitter Inc misled federal regulators about its defenses against hackers and spam accounts, the social media company’s former security chief Peiter Zatko said in a whistleblower complaint.

In an 84-page complaint, Zatko, a famed hacker widely known as “Mudge,” alleged Twitter falsely claimed it had a solid security plan, according to documents relayed by congressional investigators. Twitter’s shares fell 7.3% to close at $39.86.

The document alleges Twitter prioritized user growth over reducing spam, with executives eligible to win individual bonuses of as much as $10 million tied to increases in daily users, and nothing explicitly for cutting spam.

Twitter labeled the complaint a “false narrative.” The social media company has been battling Elon Musk in court after the world’s richest person attempted to pull out of a $44-billion deal to buy Twitter. Musk said it failed to provide details about the prevalence of bot and spam accounts.

Tesla Inc Chief Executive Musk had offered to buy Twitter for $54.20 per share, saying he believed it could be a global platform for free speech.

Twitter and Musk have sued each other, with Twitter asking a judge on the Delaware Court of Chancery to order Musk to close the deal. A trial is scheduled for Oct. 17.

Zatko filed the complaint last month with the U.S. Securities and Exchange Commission and the Department of Justice, as well as the Federal Trade Commission (FTC). The complaint was also sent to congressional committees.

“We are reviewing the redacted claims that have been published but what we have seen so far is a false narrative that is riddled with inconsistencies and inaccuracies,” Twitter Chief Executive Parag Agrawal told employees in a memo.

The Senate Judiciary Committee’s top Republican, Chuck Grassley, said the complaint raised serious national security concerns and privacy issues and needed to be investigated.

“Take a tech platform that collects massive amounts of user data, combine it with what appears to be an incredibly weak security infrastructure, and infuse it with foreign state actors with an agenda, and you’ve got a recipe for disaster,” he said.

The FTC declined to comment. A spokesperson for the Senate Intelligence Committee said it had received the complaint and was setting up a meeting to discuss the allegation.

Twitter’s real regulatory risk lies in whether the documentary evidence shows “knowing or reckless misleading” of investors or regulators, said Howard Fischer, a partner at Moses & Singer and a former SEC attorney.

‘GIVE A LITTLE WHISTLE’

Musk could not be reached for comment but reacted on Twitter with memes and emoji https://twitter.com/elonmusk/status/1562105413977493504 of a robot. Musk’s legal team has subpoenaed Zatko, CNN reported after the whistleblower disclosure was made public.

American hackers have admired Zatko since the 1990s, when he was credited with inventing a tool to crack passwords. He later used his hacking chops to become a sought-after security consultant and with other rebellious techies of the era, transitioned to top government and boardroom positions.

The whistleblower document says that after the Jan. 6 riots, the incoming Biden administration offered him “a day-one appointed position as Chief Information Security Officer for the United States,” which he turned down.

Cybersecurity leaders expressed widespread support for Zatko, and many deplored Twitter’s reaction to his revelations.

Robert Lee, founder of industrial cybersecurity company Dragos, said it was “one of the very rare times based on who it is I don’t even need to know a detail to form an opinion,” he said on Twitter. “If Mudge is making this type of claim, it deserves the investigation.”

In January, Twitter said nL1N2U11KV Zatko was no longer its head of security, two years after his appointment to the role.

On Tuesday, a Twitter spokesperson said Zatko was fired for “ineffective leadership and poor performance,” adding his allegations appeared designed to capture attention and inflict harm on Twitter, its customers and its shareholders.

Debra Katz and Alexis Ronickher, attorneys for Zatko, said in a statement that throughout his tenure at Twitter, he repeatedly raised concerns about inadequate information security systems to the company’s executive committee, CEO and board. Twitter did not respond to a request for comment on that statement.

(The story corrects closing price and removes extraneous percentage symbol in paragraph 2.)

(Reporting by Chavi Mehta, Ankur Banerjee and Tiyashi Datta in Bengaluru, Peter Henderson in Oakland and Raphael Satter in Washington; Additional reporting by Rick Cowan in Washington; Writing by Ankur Banerjee; Editing by Kenneth Li, Saumyadeb Chakrabarty, Sriraj Kalluvila and David Gregorio)

source

Chinese battery giant CATL posts strong Q2 profit on robust EV sales

Chinese battery giant CATL posts strong Q2 profit on robust EV sales 150 150 admin

SHANGHAI (Reuters) – CATL, the world’s largest electric vehicle (EV) battery manufacturer, more than doubled its profit in the second quarter as Chinese authorities rolled out incentives to boost EV sales to cushion the impact of lockdowns during the period.

CATL, whose clients include Tesla, Volkswagen and BMW, booked a net profit of 6.68 billion yuan ($974.61 million) from April to June, according to Reuters calculations based on the company’s filings, up 164% from a year ago.

Revenue also surged to 64.29 billion yuan in the three-month period, from 24.91 billion yuan a year ago, Reuters calculations showed.

The company said that a COVID outbreak during the period, which included lockdowns in several cities including Shanghai, had some impact on its domestic market. Demand, however, remained strong as local authorities rolled out incentives to promote EV sales and companies launched new models.

EV sales growth bucked an overall trend of weakening auto sales in the major markets of China, Europe and the United States, which were hit by COVID and supply chain issues, CATL said.

In China, EV sales surged 120% in the first half, while overall vehicle sales fell 6.6%, according to the China Association of Automobile Manufacturers.

Rising metal prices, especially lithium, however, weighed on CATL’s profit margin on EV batteries, which fell to 15.04% from 22% at the end of 2021.

CATL said it had taken measures including signing long-term contracts with suppliers, recycling materials and negotiating a dynamic battery pricing scheme with automakers to ease the pressure of rising costs.

The company is also accelerating its expansions in overseas markets with contracts to supply batteries to clients including Mercedes-Benz and BMW in Europe and Ford in the United States, where government incentives are driving demand for EVs.

It announced earlier this month that it would build a $7.6 billion battery plant in Hungary, Europe’s largest so far.

CATL’s market share in the global EV battery market reached 34.8% in the first half, extending its lead with a 6.2 percentage points increase from a year ago, according to data from SNE Research.

South Korea’s LG Energy Solution, which posted a 73% plunge in the second quarter profit, followed CATL with a share of 14.4%.

($1 = 6.8540 Chinese yuan renminbi)

(Reporting by Zhang Yan and Brenda Goh; Editing by Jamie Freed)

source

Exclusive-AstraZeneca may not stay in vaccines, but CEO has no COVID regrets

Exclusive-AstraZeneca may not stay in vaccines, but CEO has no COVID regrets 150 150 admin

By Aimee Donnellan and Natalie Grover

LONDON (Reuters) -AstraZeneca may not stay in the vaccine business in the long run, its CEO told Reuters on Tuesday, showing how quickly fortunes have changed for the drugmaker that produced one of the first COVID-19 shots but has since lost out to rivals. Production delays, probes by regulators following rare cases of severe side effects and concerns about its relatively short shelf life compared with other shots have stymied adoption of the company’s COVID-19 vaccine.

Now, in the third year of the pandemic amid a global vaccine supply glut, its use has diminished in much of the developed world as countries have inoculated large numbers of people and prefer Pfizer and Moderna’s mRNA vaccines as boosters.

AstraZeneca’s COVID vaccine has still not won U.S. approval.

The London-listed company is building on its portfolio of antibody therapies, including for COVID-19, the respiratory virus RSV and other viruses, Soriot said in a Reuters Newsmaker interview on Tuesday.

But on the future of its COVID vaccines business, he said: “I can’t be sure we will be there or not.”

He also said he wasn’t sure if AstraZeneca would broaden its roster of vaccines for other infections either, adding the company was looking into it.

Investors have speculated about the future of the vaccine business given slowing sales of the COVID shot as initial sales contracts have been fulfilled, stiff competition from mRNA vaccines and its relatively little expertise in the field.

The company created a separate division for vaccines and antibody therapies late last year.

Still, Soriot said he did not regret the company’s work with Oxford University to develop a COVID vaccine, given they had delivered billions of doses and saved an estimated 6 million lives across the globe.

The inoculation was AstraZeneca’s second best-selling product in 2021 with sales of $3.9 billion.

AstraZeneca is also looking for bolt-on acquisitions, including small and mid-sized companies specialising in oncology and cardiovascular treatments, Soriot added.

“We always look for external opportunities,” he said.

KEEP ON DOING THIS JOB

The CEO has presided over a quadrupling of AstraZeneca’s share price in his decade at the helm.

“I can keep doing this job for many years,” he said.

The 63-year old was once seen as a natural successor to outgoing Chairman Leif Johansson.

But in July, Soriot quashed speculation he was planning to retire any time soon, saying he expected to work with the company’s newly announced chairman-designate Michel Demare for many years to come.

Soriot was tasked with turning around a troubled AstraZeneca – hit by a string of key patent losses and a spate of clinical trial failures – in October 2012, following a stint at pharma peer Roche.

With the Frenchman at the helm, the fortunes of the Anglo-Swedish drugmaker changed dramatically after he sharpened focus on speciality medicines and the lucrative field of oncology, made acquisitions to refill the company’s medicine cabinet, fended off a hostile takeover from U.S. pharma giant Pfizer, and invested heavily in R&D to improve the company’s lacklustre drug development success rate.

However, he warned on Tuesday that fewer innovative medicines would be developed going forward due to new U.S. drug price laws.

Asked about inflationary pressures, Soriot said: “We are going to have to become more innovative and productive. We can’t expect our selling prices to go up.”

(Reporting by Aimee Donnellan and Natalie GroverEditing by Mark Potter)

source

Canada’s Scotiabank misses estimates as capital markets income slumps

Canada’s Scotiabank misses estimates as capital markets income slumps 150 150 admin

By Nichola Saminather and Manya Saini

TORONTO (Reuters) -Bank of Nova Scotia (Scotiabank) reported third-quarter profit a touch below estimates on Tuesday as a sharp drop in income from its capital markets unit overshadowed strong loan growth in its international business.

Canada’s No. 3 lender kicked off quarterly earnings reporting for the country’s biggest banks, with markets watching closely for signs of how they will be affected in future quarters by decades-high inflation and central banks’ rapid rate increases.

Scotiabank’s shares dropped 3.8% in morning trading in Toronto, the biggest intraday loss since June 2020, to C$77.72. The Toronto stock benchmark rose 0.3%.

“Overall, it was not a bad quarter, but we believe that the market’s focus will be on the headline miss and investors will be looking ahead to the uncertain outlook,” Barclays Analyst John Aiken wrote in a note.

The biggest drag on Scotiabank’s earnings came from its capital markets unit, which reported a 26% drop in profit for the three months ended July 31, as advisory and trading revenues fell in challenging market conditions.

The bank expects spending growth in its capital markets business to outpace revenue expansion this fiscal year. However, earnings should bounce back by the fourth quarter, helped in part by deals in the pipeline, executives said on a call.

Scotiabank raised its provisions for credit losses (PCL) on expectations of longer-lasting inflationary pressure and more central bank rate hikes.

Still, “we’re not seeing any big credit headwinds on the horizon,” Chief Risk Officer Philip Thomas said on the call. “The health of the consumers continues to be very, very strong.”

Adjusted pre-tax, pre-provision earnings fell 1% from a year earlier.

Scotiabank’s international business reported a 30% jump in adjusted earnings, driven by strong loan growth. But the unit’s net interest margin (NIM) slipped 1 basis point from the prior quarter, which executives attributed to higher funding costs as more customers moved to term deposits.

The Canadian business saw a 12% increase in earnings.

Scotiabank said net income excluding one-off items came to C$2.10 a share, up from C$2.01 a year earlier. Analysts had expected C$2.11 a share.

Scotiabank shares are now down 14.8% since the start of this year.

($1 = 1.3021 Canadian dollars)

(Reporting by Nichola Saminather in Toronto and Manya Saini in Bengaluru; Editing by Krishna Chandra Eluri and Susan Fenton)

source

Exclusive: AstraZeneca may not stay in vaccines, but CEO has no COVID regrets

Exclusive: AstraZeneca may not stay in vaccines, but CEO has no COVID regrets 150 150 admin

By Aimee Donnellan and Natalie Grover

LONDON (Reuters) – AstraZeneca may not stay in the vaccine business in the long run, its CEO told Reuters on Tuesday, showing how quickly fortunes have changed for the drugmaker that produced one of the first COVID-19 shots but has since lost out to rivals. Production delays, probes by regulators following rare cases of severe side effects, and concerns about its relatively short shelf life compared with other shots have stymied adoption of the company’s COVID-19 vaccine.

Now, in the third year of the pandemic amid a global vaccine supply glut, its use has diminished in much of the developed world as countries have inoculated large numbers of people and prefer Pfizer and Moderna’s mRNA vaccines as boosters.

AstraZeneca’s COVID vaccine has still not won U.S. approval.

The London-listed company is building on its portfolio of antibody therapies, including for COVID-19, the respiratory virus RSV and other viruses, Soriot said in a Reuters Newsmaker interview on Tuesday.

But on the future of its COVID vaccines business, he said: “I can’t be sure we will be there or not.”

He also said he wasn’t sure if AstraZeneca would broaden its roster of vaccines for other infections either, adding that the company was looking into it.

Investors have speculated about the future of the vaccine business given slowing sales of the COVID shot as initial sales contracts have been fulfilled, stiff competition from mRNA vaccines and its relatively little expertise in the field.

The company created a separate division for vaccines and antibody therapies late last year.

Still, Soriot said he did not regret the company’s work with Oxford University to develop a COVID vaccine, given they had delivered billions of doses and saved an estimated 6 million lives across the globe.

The inoculation was AstraZeneca’s second best-selling product in 2021 with sales of $3.9 billion.

AstraZeneca is also looking for bolt-on acquisitions, including small and mid-sized companies specialising in oncology and cardiovascular treatments, Soriot added.

“We always look for external opportunities,” he said.

KEEP ON DOING THIS JOB

The CEO has presided over a quadrupling of AstraZeneca’s share price in his decade at the helm.

“I can keep doing this job for many years,” he said.

The 63-year old was once seen as a natural successor to outgoing Chairman Leif Johansson.

But in July, Soriot quashed speculation he was planning to retire any time soon, saying he expected to work with the company’s newly announced chairman-designate Michel Demare for many years to come.

Soriot was tasked with turning around a troubled AstraZeneca – hit by a string of key patent losses and a spate of clinical trial failures – in October 2012, following a stint at pharma peer Roche.

With the Frenchman at the helm, the fortunes of the Anglo-Swedish drugmaker changed dramatically.

He sharpened focus on speciality medicines and the lucrative field of oncology, made acquisitions to refill the company’s medicine cabinet, fended off a hostile takeover from U.S. pharma giant Pfizer, and invested heavily in R&D to improve the company’s lacklustre drug development success rate.

However, he warned on Tuesday that fewer new medicines would be developed going forward due to U.S. drug price laws passed last week.

Asked about inflationary pressures, Soriot said: “We are going to have to become more innovative and productive. We can’t expect our selling prices to go up.”

Sales in China, which account for close to a fifth of the company’s total annual revenue, have dipped in recent quarters due to lower drug prices and as COVID lockdown measures kept some patients from being diagnosed and seeking cancer care.

On Tuesday, Soriot said sales were picking up in the third quarter in the world’s second-largest market for pharmaceuticals – and he expected the country to play a more significant role in the global market over the next decade.

(Reporting by Aimee Donnellan and Natalie Grover; Editing by Mark Potter and Jan Harvey)

source

U.S. new home sales dive to 6-1/2-year low; prices remain high

U.S. new home sales dive to 6-1/2-year low; prices remain high 150 150 admin

By Lucia Mutikani

WASHINGTON (Reuters) -Sales of new U.S. single-family homes plunged to a 6-1/2-year low in July as persistently high mortgage rates and house prices further eroded affordability.

The housing market has been the sector hardest hit by the aggressive interest rate increases delivered by the Federal Reserve to tame inflation. The report from the Commerce Department on Tuesday added to a stream of weak housing data.

New home sales tumbled 12.6% to a seasonally adjusted annual rate of 511,000 units last month, the lowest level since January 2016. June’s sales pace was revised down to 585,000 units from the previously reported 590,000 units.

Sales rose in the Northeast, but dove in the West and the Midwest as well as the densely populated South.

Economists polled by Reuters had forecast that new home sales, which account for a fraction of U.S. home sales, would decrease to a rate of 575,000 units.

Sales dropped 29.6% on a year-on-year basis in July. They peaked at a rate of 993,000 units in January 2021, which was the highest level since the end of 2006.

Data last week showed single-family housing starts, which account for the biggest share of homebuilding, tumbled to a two-year low in July, while home resales fell to levels last seen in May 2020. The National Association of Home Builders/Wells Fargo Housing Market sentiment index fell below the break-even level of 50 in August for the first time since May 2020.

The Fed has hiked its policy rate by 225 basis points since March to slow the economy and, in turn, curb inflation.

Fed Chair Jerome Powell’s address on Friday at the annual Jackson Hole global central banking conference in Wyoming could signal how much further the U.S. central bank needs to tighten monetary policy.

Mortgage rates, which move in tandem with U.S. Treasury yields, have soared even higher than the Fed’s benchmark overnight interest rate. The 30-year fixed-rate mortgage is averaging 5.13%, up from 3.22% at the start of the year, according to data from mortgage finance agency Freddie Mac.

Despite slowing demand, house price growth remains strong. The median new house price in July was $439,400, an 8.2% jump from a year ago. There were 464,000 new homes on the market at the end of last month, up from 450,000 units in June.

Houses under construction made up roughly 67.2% of the inventory, with homes yet to be built accounting for about 23.1%. At July’s sales pace it would take 10.9 months to clear the supply of houses on the market, up from 9.2 months in June.

(Reporting by Lucia MutikaniEditing by Chizu Nomiyama and Paul Simao)

source

World at rising risk of recession as inflation hits consumers

World at rising risk of recession as inflation hits consumers 150 150 admin

By Jonathan Cable

LONDON (Reuters) – The global economy is increasingly at risk of sliding into recession, surveys showed on Tuesday, as consumers faced with generation-high inflation rein in spending while central banks are tightening policy aggressively just when support is needed.

And supply chains yet to recover from the coronavirus pandemic have been further damaged by Russia’s invasion of Ukraine and China’s strict COVID-19 lockdowns, hurting the manufacturing industry.

A myriad of purchasing managers’ surveys published on Tuesday from Asia to Europe to the United States showed business activity contracting and pointed to little hope of a turnaround anytime soon.

“Put simply, it’s the extremely high rates of inflation that is resulting in households having to pay more for the goods and services they have to buy which means they have less to spend on other items,” said Paul Dales at Capital.

“That’s a reduction in economic output so that’s what’s driving the recession. Higher interest rates are playing a small part but really it’s the higher inflation.”

U.S. private-sector business activity contracted for a second straight month in August and is at its weakest in 18 months, with particular softness registered in the services sector.

There is a 45% chance of a U.S. recession within a year and 50% within two years, according to economists in a Reuters poll on Monday who did however largely say it would be short and shallow. [ECILT/US]

It was a similar story in the euro zone where the cost of living crisis meant customers kept their hands in their pockets and business activity across the bloc contracted for a second month.

The gloomy data pinned the euro to a 20-year low against the dollar, with surging gas prices adding to misery dragging Europe towards recession.

In Britain, outside the European Union, private sector growth slowed to a crawl as factory output fell and the larger services sector eked out only a modest expansion, indicating a recession was coming there.

Japan’s factory growth slowed to a 19-month low this month as output and new order declines deepened while Australia’s composite Purchasing Managers’ Index fell below the 50 mark separating growth from contraction.

FEELING THE PINCH

Inflation has reached multi-decade highs in many parts of the world, forcing central banks to tighten monetary policy as their mandate is to maintain price stability.

The Federal Reserve has lifted its benchmark overnight interest rate by 2.25 percentage points this year as it tries to curb decades-high inflation and is expected to raise it again next month, a Reuters poll found on Monday. [ECILT/US]

Yet despite that aggressive policy inflation was likely to stay above the Fed’s target beyond this year and next.

Last month the Bank of Canada surprised markets with a larger than expected 100 basis point increase to its key interest rate and said more hikes would be needed.

The European Central Bank, which struggled to get any meaningful inflation for years but is now facing it well above target, kicked off its rate hiking cycle in July, raising interest rates more than expected and a Reuters poll forecasts it will continue on its tightening path. [ECILT/EU]

Britain’s Bank of England was one of the first amongst its peers to raise borrowing costs and is widely expected to continue doing so, even though it has warned the country faces a long recession as energy bills are expected to push consumer price inflation above 13% in October. [ECILT/GB]

Central banking heavyweights, including Fed Chair Jerome Powell, meet this week for their annual symposium in Jackson Hole, Wyoming, and may shed light on how big future rate hikes might be and how strong their economies are.

“Following the signs of an end to rate hikes among the central banks which led the tightening, investors may anticipate that the Fed, ECB, and BoE may end their rate hikes in the first half of 2023,” said Richard Flynn at Charles Schwab.

“This year’s Symposium may provide an early indication of when the turn from hikes to cuts may occur.”

(Reporting by Jonathan Cable; Editing by Nick Macfie)

source

AstraZeneca’s Soriot warns new U.S. drug price law will hurt innovation

AstraZeneca’s Soriot warns new U.S. drug price law will hurt innovation 150 150 admin

By Aimee Donnellan and Natalie Grover

LONDON (Reuters) -AstraZeneca’s Chief Executive Pascal Soriot warned on Tuesday new U.S. legislation capping drug prices would reduce the ability of companies to recoup their investment on developing new drugs and hurt innovation.

In a Reuters Newsmaker interview, he said the British drugmaker’s top-selling cancer therapy Tagrisso as well as its potential blockbuster Enhertu would likely be negatively affected by the new law in the coming years.

Last week, a landmark law that included provisions to tackle the rising cost of medicines was passed in the United States, in a rare legislative defeat for the powerful pharmaceutical industry that set a precedent for curbing drug prices in the world’s most lucrative market for medicines.

The act will for the first time allow the federal Medicare health plan for the elderly and disabled to negotiate prices on up to 20 drugs a year. It also sets limits on drug price increases for Medicare and caps out-of-pocket costs for those enrolled in the programme.

The price negotiation portion of the legislation, which will kick off from 2026, poses a significant challenge, Soriot said.

He said it was unclear how such negotiations would play out, and that it appeared to be structured as less of a negotiation and more of an “imposition of price.”

With the current system of patent protection, pharmaceutical companies are able to recoup their investment in developing a drug drugs over nine to 11 years. With this new law, the potential to recoup that investment is curtailed, he said.

(Reporting by Aimee Donnellan and Natalie GroverEditing by Mark Potter)

source